Even though diagnosis of prostate cancer can be made earlier than in the past, prognosis is still difficult. The discovery of new metastatic markers should aid in treatment design.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boring, C.C., Squires, T.S. & Tong, T. Cancer statistics. CA 45, 8–31 (1995).
Partin, A.W. et al. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol. Clin. North Am. 20, 713–725 (1993).
Stamey, T.A. et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy patients. J. Urol. 141, 1076–1083 (1989).
Partin, A.W. et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45, 831–837 (1995).
Thompson, T.C. Growth factors and oncogenes in prostate cancer. Cancer Cells 2, 345–354 (1990).
Fishman, J.R., Gumerlock, P.H., Meyers, F.J. & De Vere White, R.W. Quantitation of NM23 expression in human prostate cancer tissues. J. Urol. 152, 202–207 (1994).
Dong, J.T. et al. KAI1, a metastases suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268, 884–886 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Petrylak, D. Metastases suppressors and prostate cancer. Nat Med 1, 739–740 (1995). https://doi.org/10.1038/nm0895-739
Issue Date:
DOI: https://doi.org/10.1038/nm0895-739
